drugset
Drugs / Hypertonic 3% saline
last change Aug 2026 re-read 2 minutes ago

Hypertonic 3% saline

Developed for
pulpitis
Investigated by
Cairo University

Trials 1 · a red edge is where a trial was stopped

today NCT07701551 · Ph 4
2027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 4 NCT07701551 Aug 2026 → Jan 2027 expected pulpitis Cairo University Not yet recruiting No outcome recorded
Also used as a comparator or background therapy in 1 trial
PhaseRegistry idDatesIndicationSponsorStatusOutcome
— NCT02719210 Comparator Jan 2016 → Nov 2018 acute liver failure Institute of Liver and Biliary Sciences, India Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as Hypertonic 3% saline ClinicalTrials.gov intervention name — accepted as the source's own label NCT02719210 ↗
1

NCT07701551 ↗
Action Inhibit “suppress pro-inflammatory cytokine-mediated SP release via NF-κB pathway inhibition.” NCT07701551 ↗
Route Other “5 mL 0.9% normal saline (control) or 5 mL 3% hypertonic saline (intervention), delivered via a 30-gauge side-vented needle 2 mm short of working length.” NCT07701551 ↗